Metabolic syndrome increases the risk of aggressive prostate cancer detection

Juan Morote, Jordi Ropero, Jacques Planas, Juan M. Bastarós, Gueisy Delgado, José Placer, Anna Celma, Inés M. De Torres, Joan Carles, Jaume Reventós, Andreas Doll

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

47 Cites (Scopus)

Resum

Objective To further examine the association between metabolic syndrome (MS), prostate cancer (PC) detection risk and tumour aggressiveness. Patients and Methods From 2006 to 2010, 2408 men not receiving 5α-reductase inhibitors were scheduled for prostatic biopsy due to PSA above 4 ng/mL and/or abnormal digital rectal examination. MS was evaluated according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III definition. Tumour aggressiveness was evaluated through biopsy Gleason score, clinical stage and risk of biochemical recurrence after primary treatment. Results The rates of PC detection were 34.5% and 36.4% respectively in men with and without MS, P = 0.185. High grade PC rates (Gleason score 8-10) were 35.9% and 23.9% respectively, P < 0.001. The advanced disease rates (cT3-4 N0-1 M0-1) were 17% and 12.7% respectively, P = 0.841. The high risk PC rates (cT2c-4 or Gleason score 8-10 or PSA > 20) were 38.5% and 33.0% respectively, P = 0.581. Multivariate analysis confirmed that MS was not associated with the risk of PC detection but it was associated with an increased risk of high grade tumours (odds ratio 1.75, 95% CI 1.26-2.41), P < 0.001. Conclusion MS seems not be associated with an increased risk of PC detection but it is associated with an increased risk of more aggressive tumours. © 2012 BJU International.
Idioma originalAnglès
Pàgines (de-a)1031-1036
RevistaBJU International
Volum111
Número7
DOIs
Estat de la publicacióPublicada - 1 de juny 2013

Fingerprint

Navegar pels temes de recerca de 'Metabolic syndrome increases the risk of aggressive prostate cancer detection'. Junts formen un fingerprint únic.

Com citar-ho